These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 16126841)

  • 1. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
    Hansen RJ; Nagasubramanian R; Delaney SM; Cherian MM; Lin S; Kogan SC; Dolan ME
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1247-55. PubMed ID: 16126841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
    Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
    Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea.
    Loktionova NA; Pegg AE
    Cancer Res; 1996 Apr; 56(7):1578-83. PubMed ID: 8603405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
    Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE
    Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
    Gajewski TF; Sosman J; Gerson SL; Liu L; Dolan E; Lin S; Vokes EE
    Clin Cancer Res; 2005 Nov; 11(21):7861-5. PubMed ID: 16278409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.
    Apisarnthanarax N; Wood GS; Stevens SR; Carlson S; Chan DV; Liu L; Szabo SK; Fu P; Gilliam AC; Gerson SL; Remick SC; Cooper KD
    Arch Dermatol; 2012 May; 148(5):613-20. PubMed ID: 22250189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
    Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
    Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).
    Dolan ME; Pegg AE; Moschel RC; Grindey GB
    Biochem Pharmacol; 1993 Jul; 46(2):285-90. PubMed ID: 8347150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU.
    Schold SC; Kokkinakis DM; Rudy JL; Moschel RC; Pegg AE
    Cancer Res; 1996 May; 56(9):2076-81. PubMed ID: 8616853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer.
    Dolan ME; Pegg AE; Biser ND; Moschel RC; English HF
    Cancer Chemother Pharmacol; 1993; 32(3):221-5. PubMed ID: 8500228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents.
    Kokkinakis DM; Ahmed MM; Delgado R; Fruitwala MM; Mohiuddin M; Albores-Saavedra J
    Cancer Res; 1997 Dec; 57(23):5360-8. PubMed ID: 9393761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
    Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
    Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Felker GM; Friedman HS; Dolan ME; Moschel RC; Schold C
    Cancer Chemother Pharmacol; 1993; 32(6):471-6. PubMed ID: 8258196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone.
    Gerson SL; Zborowska E; Norton K; Gordon NH; Willson JK
    Biochem Pharmacol; 1993 Jan; 45(2):483-91. PubMed ID: 8435098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
    Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
    Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
    Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
    Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Davis BM; Reese JS; Koç ON; Lee K; Schupp JE; Gerson SL
    Cancer Res; 1997 Nov; 57(22):5093-9. PubMed ID: 9371508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of human medulloblastoma tumor xenografts with a combination of O6-benzyl-2'-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea.
    Kokkinakis DM; Moschel RC; Pegg AE; Schold SC
    Clin Cancer Res; 1999 Nov; 5(11):3676-81. PubMed ID: 10589786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
    Friedman HS; Dolan ME; Moschel RC; Pegg AE; Felker GM; Rich J; Bigner DD; Schold SC
    J Natl Cancer Inst; 1992 Dec; 84(24):1926-31. PubMed ID: 1334154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.
    Mitchell RB; Moschel RC; Dolan ME
    Cancer Res; 1992 Mar; 52(5):1171-5. PubMed ID: 1737376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.